Isoquinolone Derivatives for Melatonin Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current melatonin receptor agonists lack selectivity and stability, limiting their effectiveness in treating disorders related to melatonin receptors due to short biological half-life and poor oral bioavailability.
Innovation Solution
Development of isoquinolone derivatives with specific substituents that exhibit high affinity and selectivity for melatonin receptors MT1 and MT2, synthesized through combinatorial chemistry and high-throughput screening to modulate melatonin receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current melatonin receptor agonists are used, then melatonin receptor activity is modulated, but selectivity and stability are poor leading to limited effectiveness
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of melatonin receptor agonists through isoquinolone derivatives with specific substituent patterns. The core isoquinolone structure with defined R1-R7 substituents creates compounds with optimized pharmacokinetic properties including improved stability and oral bioavailability while maintaining receptor modulatory activity
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecular structures that combine the isoquinolone core with various functional substituents. This composite approach allows integration of multiple pharmacophoric elements within a single molecule, achieving both high affinity for melatonin receptors and improved metabolic stability
2Reliability
If current melatonin receptor agonists are used, then melatonin receptor activity is modulated, but selectivity is poor limiting therapeutic effectiveness
Solution Approach 1:
The patent applies local quality principles by introducing specific substituent patterns at defined positions (R1-R7) on the isoquinolone core. These localized structural modifications create distinct molecular recognition features that enhance selectivity for specific melatonin receptor subtypes while maintaining overall receptor modulatory activity
Solution Approach 2:
The patent employs segmentation by dividing the molecular structure into distinct functional regions: the core isoquinolone scaffold providing basic pharmacophoric activity, and variable R1-R7 substituents providing selectivity-determining features. This segmentation allows independent optimization of affinity and selectivity properties
3Reliability
If current melatonin receptor agonists are used, then some therapeutic benefit is achieved, but biological half-life is short reducing effectiveness
Solution Approach 1:
The patent applies preliminary action by incorporating metabolically stable chemical structures into the agonist design before administration. The isoquinolone core with specific substituent patterns is pre-configured to resist metabolic degradation, thereby extending biological half-life and duration of action before the compound enters the biological system
4Reliability
If current melatonin receptor agonists are used, then some therapeutic benefit is achieved, but oral bioavailability is poor limiting effectiveness
Solution Approach 1:
The patent applies parameter changes by optimizing physicochemical properties of the agonist molecules through isoquinolone derivative design. Modifications to molecular weight, lipophilicity, and hydrogen bonding capacity within the R1-R7 substituent patterns improve oral absorption and bioavailability while maintaining receptor affinity
Data Source
AI summary
A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor,R1, R2, R3, R4 and R7 are independently H, halo, alkyloxyl, alkyl or hydroxyl, provided that one of R1, R2, R3 and R7 is X—(CH2)n—R8; R5 is alkyl or arylalkyl; R6 is H or alkyl; X is a bond, O, S, SO, SO2, CO or NH; n=0-10; R8 is alkenyl, substituted or unsubstituted aryl, NR9R10, or OR9; R9 is H, substituted or unsubstituted arylmethyl, or alkenyl; and R10 is H or alkyl.